Revolution Medicines, Inc. RVMD
193.06 USD -7.09 (-3.54%)
At closeNov 10, 2026, 5:50 PM EST
190.57 -2.49 -1.29%
After hours · Nov 10, 5:50 PM ET
189.76 Day range 198.95
62.29 52-week range 224.31
- YTD
- +142.39%
- 1 year
- +207.76%
News
seekingalpha.com Revolution Medicines, Inc. (RVMD) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript Revolution Medicines, Inc. ( RVMD ) 3rd Annual Guggenheim Healthcare Innovation Conference November 10, 2026 8:30 AM EST Company Participants Mark Goldsmith - CEO, President & Chairman Presentation…
zacks.com Wall Street Analysts Think Revolution Medicines (RVMD) Could Surge 33.34%: Read This Before Placing a Bet The consensus price target hints at a 33.3% upside potential for Revolution Medicines (RVMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in…
benzinga.com HC Wainwright & Co. Maintains Buy on Revolution Medicines, Raises Price Target to $350 HC Wainwright & Co. analyst Robert Burns maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $280 to $350.
benzinga.com TD Cowen Maintains Buy on Revolution Medicines, Raises Price Target to $270 TD Cowen analyst Tyler Van Buren maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $250 to $270.
benzinga.com RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $321 RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $260 to $321.
benzinga.com Piper Sandler Maintains Overweight on Revolution Medicines, Raises Price Target to $222 Piper Sandler analyst Kelsey Goodwin maintains Revolution Medicines (NASDAQ:RVMD) with a Overweight and raises the price target from $210 to $222.
benzinga.com Truist Securities Reiterates Buy on Revolution Medicines, Raises Price Target to $261 Truist Securities analyst Gregory Renza reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $241 to $261.- benzinga.com Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $298 Guggenheim analyst Michael Schmitz maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $275 to $298.
- benzinga.com Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $340 Evercore ISI Group analyst Cory Kasimov maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $320 to $340.
defenseworld.net What Revolution Medicines (RVMD) Said on Its Q3 Earnings Call Revolution Medicines (NASDAQ: RVMD) reported $197.6 million in third-quarter net product revenue from its newly approved pancreatic cancer treatment RASONQUE, reflecting roughly five weeks of U.S.…
marketbeat.com What Revolution Medicines (RVMD) Said on Its Q3 Earnings Call Revolution Medicines NASDAQ: RVMD reported $197.6 million in third-quarter net product revenue from its newly approved pancreatic cancer treatment RASONQUE, reflecting roughly five weeks of U.S.…
seekingalpha.com Revolution Medicines, Inc. (RVMD) Q3 2026 Earnings Call Transcript Revolution Medicines, Inc. (RVMD) Q3 2026 Earnings Call Transcript
zacks.com Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Beats Revenue Estimates Revolution Medicines, Inc. (RVMD) came out with a quarterly loss of $1.9 per share versus the Zacks Consensus Estimate of a loss of $2.34. This compares to a loss of $1.61 per share a year ago.
benzinga.com Revolution Medicines Q3 2026 Earnings Call Transcript Revolution Medicines (NASDAQ:RVMD) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Revolution Medicines (NASDAQ:RVMD) stock rose 14.1% to $227.83 during Wednesday's after-market session. The market value of their outstanding shares is at $41.6 billion. As per the news, the…- benzinga.com Revolution Medicines Q3 EPS $(1.90) Beats $(2.42) Estimate, Sales $197.559M May Not Be Comparable To $23.495M Estimate Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(1.90) per share which beat the analyst consensus estimate of $(2.42) by 21.49 percent. This is a 18.01 percent decrease over losses…
globenewswire.com Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress Received U.S. FDA approval and launched RASONQUE® (daraxonrasib) for adult patients with metastatic pancreatic cancer who have received at least one prior systemic therapy or who are not candidates…
benzinga.com ARM, McDonald's On Deck Wednesday As AI Demand, Consumer Spending Face Test ARM Holdings headlines Wednesday’s reports, with investors looking for evidence that AI-related demand can support the chip designer after a sharp stock pullback. McDonald’s, Novo Nordisk, Uber…
benzinga.com Earnings Volatility Watch: 10 Stocks Are Set to Swing More Than 10% This Week Ten stocks carry implied earnings moves above 10% next week, led by Moderna and AppLovin. Five are tech names hit in Friday's chip rout.
benzinga.com Jim Cramer: This Tech Stock ‘Sells At A Low Multiple’ Jim Cramer favors Penguin Solutions for its low valuation after strong earnings and says investors should let Revolution Medicines run.
benzinga.com Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data? Tango Therapeutics reports an 82% response rate in pancreatic cancer trials and prepares a randomized registrational study for early 2027.
benzinga.com Here’s How Much You Would Have Made Owning Revolution Medicines Stock In The Last 5 Years Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 35.96% on an annualized basis producing an average annual return of 46.71%. Currently, Revolution Medicines has…- benzinga.com Revolution Medicines Presents Exploratory Subgroup Analyses From Phase 3 RASolute 302 Trial, As Late-Breaking Abstract At ESMO Congress 2026 Expanding on the unprecedented final results previously reported from the Phase 3 RASolute 302 trial, the exploratory subgroup analyses showed RASONQUE consistently provided an overall survival…
- benzinga.com Tango Therapeutics Announces Results From Ongoing Phase 1/2 Study Of Vopimetostat In Combination With Daraxonrasib In Patients With Metastatic Pancreatic Ductal Adenocarcinoma And Non-Small Cell Lung Cancer; Study Demonstrated 82% Objective Response Rate, Median PFS Not Yet Reached, And 9M PFS Rate Of 88%, In 22 Patients Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to delivering breakthrough targeted therapies that extend and improve the lives of patients with cancer, today…
benzinga.com TD Cowen Reiterates Buy on Revolution Medicines, Announces $250 Price Target TD Cowen analyst Tyler Van Buren reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and announces $250 price target.
benzinga.com Revolution Medicines Begins Phase 3 Trial For Advanced Lung Cancer Treatment Revolution Medicines doses first patients in its global Phase 3 trial testing zoldonrasib for metastatic non-small cell lung cancer.- benzinga.com Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $241 Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $240 to $241.
benzinga.com Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow William Blair sets $226 price target for Revolution Medicines (RVMD) following Rasonque approval and major oncology expansion plans.- benzinga.com William Blair Initiates Coverage On Revolution Medicines with Outperform Rating William Blair analyst Alethia Young initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Outperform rating.
- benzinga.com Needham Reiterates Buy on Revolution Medicines, Maintains $275 Price Target Needham analyst Ami Fadia reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and maintains $275 price target.
benzinga.com Here's How Much $1000 Invested In Revolution Medicines 5 Years Ago Would Be Worth Today Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 36.7% on an annualized basis producing an average annual return of 48.0%. Currently, Revolution Medicines has a…
benzinga.com RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $260 RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $259 to $260.
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Stock Market Today: S&P 500 Slips as Oil Spikes 5%, 10-Year Yields Near 5.35% Stocks slip as Gulf tanker attacks lift Brent above $105 and the 10-year yield nears 5.35%; small caps lag while energy and Chipotle rally.- benzinga.com RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $259 RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $251 to $259.
- benzinga.com Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $240 Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $239 to $240.
- benzinga.com Revolution Medicines Begins Treating Patients In RASolute 309, Global, Randomized Phase 3 Clinical Trial Evaluating Combination Of RASONQUE And Zoldonrasib As First-Line Treatment In Adult Patients With Metastatic RAS G12D PDAC Revolution Medicines, Inc. (NASDAQ:RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers,…
- benzinga.com Brookline Capital Initiates Coverage On Revolution Medicines with Buy Rating, Announces Price Target of $318 Brookline Capital analyst Leah Rush initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Buy rating and announces Price Target of $318.
- benzinga.com Goldman Sachs Reinstates Buy on Revolution Medicines, Announces $267 Price Target Goldman Sachs analyst Andrea Newkirk reinstates Revolution Medicines (NASDAQ:RVMD) with a Buy and announces $267 price target.
- benzinga.com Here's How Much $1000 Invested In Revolution Medicines 5 Years Ago Would Be Worth Today Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 33.5% on an annualized basis producing an average annual return of 45.32%. Currently, Revolution Medicines has…
- benzinga.com B of A Securities Maintains Buy on Revolution Medicines, Raises Price Target to $265 B of A Securities analyst Alec Stranahan maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $225 to $265.
benzinga.com Morgan Stanley Initiates Coverage On Revolution Medicines with Overweight Rating, Announces Price Target of $255 Morgan Stanley analyst Sean Laaman initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Overweight rating and announces Price Target of $255.- benzinga.com Stifel Maintains Buy on Revolution Medicines, Raises Price Target to $230 Stifel analyst Laura Prendergast maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $215 to $230.
benzinga.com $100 Invested In Revolution Medicines 5 Years Ago Would Be Worth This Much Today Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 35.53% on an annualized basis producing an average annual return of 46.85%. Currently, Revolution Medicines has…- benzinga.com Reported Earlier, Revolution Medicines Lung Cancer Drug Shows 42% Response Rate In Early Trial Revolution Medicines, Inc. (NASDAQ:RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers,…
benzinga.com Why Are 42% of US Cancer Patients Draining Their Life Savings in Two Years? Bernie Sanders Has a $400,000 Answer Bernie Sanders blasts Big Pharma over $400,000 cancer drugs, warning soaring treatment costs can push patients into financial ruin.
benzinga.com SLS Stock Looks Like a $3 Billion Biotech Winner—This Short Seller Says the Market Has It Dangerously Wrong: 'Most Expensive Coin Flip' (UPDATED) Short seller BMF Capital disclosed a short position in SELLAS Life Sciences, arguing the market has 'dangerously overvalued' the biotech.
benzinga.com Snowflake To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Monday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BMO…- benzinga.com Needham Maintains Buy on Revolution Medicines, Raises Price Target to $275 Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $240 to $275.
- benzinga.com UBS Maintains Buy on Revolution Medicines, Raises Price Target to $265 UBS analyst Michael Yee maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $220 to $265.